目的:观察微小核糖核酸-134-5p(mi R-134-5p)转染对宫颈癌细胞增殖和凋亡的影响,验证其可能的分子机制。方法:收集湖北医药学院附属人民医院肿瘤中心2016年5月至8月收治的8名宫颈癌患者肿瘤组织和相应癌旁组织。利用lipofectamine 2000...目的:观察微小核糖核酸-134-5p(mi R-134-5p)转染对宫颈癌细胞增殖和凋亡的影响,验证其可能的分子机制。方法:收集湖北医药学院附属人民医院肿瘤中心2016年5月至8月收治的8名宫颈癌患者肿瘤组织和相应癌旁组织。利用lipofectamine 2000将mi R-134-5p mimics转染至宫颈癌Hela和Si Ha细胞。采用MTT法和集落形成实验检测细胞增殖活性;流式细胞术(FCM)检测细胞周期和细胞凋亡;q RT-PCR检测宫颈癌组织和细胞mi R-134-5p m RNA表达以及宫颈癌细胞EGFR m RNA表达;Western blotting检测宫颈癌细胞EGFR信号通路相关蛋白的表达。结果:宫颈癌组织mi R-134-5p m RNA表达显著低于癌旁组织(P<0.01)。和转染mi R-NC的Hela和Si Ha细胞比较,转染mi R-134-5pmimics的宫颈癌Hela和Si Ha细胞mi R-134-5p m RNA表达显著升高;细胞增殖能力显著降低(转染第5天,Hela细胞:1.06±0.13 vs 1.32±0.07;Si Ha细胞:1.12±0.10 vs 1.42±0.12,均P<0.05);形成的集落数减少;G0/G1期细胞比例显著上升,S期和G2/M期细胞比例显著下降;细胞凋亡率显著增加[Hela细胞:(26.53±13.48)%vs(3.25±1.74)%;Si Ha细胞:(30.49±12.04)%vs(5.10±2.86)%,均P<0.05];EGFR m RNA和EGFR蛋白表达显著下调,其中EGFR m RNA,Hela细胞下调58%(P<0.01),Si Ha细胞下调41%(P<0.05);EGFR下游靶蛋白p-AKT、p-ERK1/2和Cyclin D1蛋白及p EGFR蛋白表达显著下调。结论:mi R-134-5p可显著抑制宫颈癌细胞增殖并促进细胞凋亡,其可能的分子机制是通过抑制EGFR基因的表达,抑制EGFR通路的活化。展开更多
Background： Current understanding of tumor biology suggests that breast cancer is a group of diseases with different intrinsic molecular subtypes. Anatomic staging system alone is insufficient to provide future outco...Background： Current understanding of tumor biology suggests that breast cancer is a group of diseases with different intrinsic molecular subtypes. Anatomic staging system alone is insufficient to provide future outcome information. The American Joint Committee on Cancer （AJCC） expert panel updated the 8th edition of the staging manual with prognostic stage groups by incorporating biomarkers into the anatomic stage groups. In this study, we retrospectively analyzed the data from our center in China using the anatomic and prognostic staging system based on the AJCC 8th edition staging manual. Methods： We reviewed the data from January 2008 to December 2014 for cases with Luminal B Human Epidermal Growth Factor Receptor 2 （HER2）-negative breast cancer in our center. All cases were restaged using the AJCC 8th edition anatomic and prognostic staging system. The Kaplan-Meier method and log-rank test were used to compare the survival differences between different subgroups. SPSS software version 19.0 （IBM Corp., Armonk, NY, USA） was used for the statistical analyses. Results： This study consisted of 796 patients with Luminal B HER-negative breast cancer. The 5-year disease-free survival （DFS） of 769 Stage I-III patients was 89.7%, and the 5-year overall survival （OS） of all 796 patients was 91.7%. Both 5-year DFS and 5-year OS were significantly different in the different anatomic and prognostic stage groups, There were 372 cases （46.7%） assigned to a different group. The prognostic Stage II and III patients restaged from anatomic Stage III had significant differences in 5-year DFS （v2 = 11.319; P = 0.001） and 5-year OS （χ2 = 5.225, P = 0.022）. In addition, cases restaged as prognostic Stage I, II, or III from the anatomic Stage II group had statistically significant differences in 5-year DFS （χ2 = 6.510, P = 0.039） but no significant differences in 5-year OS （χ2 = 5.087, P = 0.079）. However, the restaged prognostic Stage I and II cases from anatomic Stage I had no statistically significant differences in either 5-year DFS （χ2 = 0.440, P = 0.507） or 5-year OS （χ2= 1.530, P = 0.216）. Conclusions： The prognostic staging system proposed in the AJCC 8th edition refines the anatomic stage group in Luminal B HER2-negative breast cancer and will lead to a more personalized approach to breast cancer treatment.展开更多
1文献来源 Becker A, Crombag L, Heideman DA, et al. Retreatment with Erlotinib： Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment [J]. Eur J Cance...1文献来源 Becker A, Crombag L, Heideman DA, et al. Retreatment with Erlotinib： Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment [J]. Eur J Cancer, 2011,47（17） ：2603-2606.2展开更多
文摘目的:观察微小核糖核酸-134-5p(mi R-134-5p)转染对宫颈癌细胞增殖和凋亡的影响,验证其可能的分子机制。方法:收集湖北医药学院附属人民医院肿瘤中心2016年5月至8月收治的8名宫颈癌患者肿瘤组织和相应癌旁组织。利用lipofectamine 2000将mi R-134-5p mimics转染至宫颈癌Hela和Si Ha细胞。采用MTT法和集落形成实验检测细胞增殖活性;流式细胞术(FCM)检测细胞周期和细胞凋亡;q RT-PCR检测宫颈癌组织和细胞mi R-134-5p m RNA表达以及宫颈癌细胞EGFR m RNA表达;Western blotting检测宫颈癌细胞EGFR信号通路相关蛋白的表达。结果:宫颈癌组织mi R-134-5p m RNA表达显著低于癌旁组织(P<0.01)。和转染mi R-NC的Hela和Si Ha细胞比较,转染mi R-134-5pmimics的宫颈癌Hela和Si Ha细胞mi R-134-5p m RNA表达显著升高;细胞增殖能力显著降低(转染第5天,Hela细胞:1.06±0.13 vs 1.32±0.07;Si Ha细胞:1.12±0.10 vs 1.42±0.12,均P<0.05);形成的集落数减少;G0/G1期细胞比例显著上升,S期和G2/M期细胞比例显著下降;细胞凋亡率显著增加[Hela细胞:(26.53±13.48)%vs(3.25±1.74)%;Si Ha细胞:(30.49±12.04)%vs(5.10±2.86)%,均P<0.05];EGFR m RNA和EGFR蛋白表达显著下调,其中EGFR m RNA,Hela细胞下调58%(P<0.01),Si Ha细胞下调41%(P<0.05);EGFR下游靶蛋白p-AKT、p-ERK1/2和Cyclin D1蛋白及p EGFR蛋白表达显著下调。结论:mi R-134-5p可显著抑制宫颈癌细胞增殖并促进细胞凋亡,其可能的分子机制是通过抑制EGFR基因的表达,抑制EGFR通路的活化。
文摘Background： Current understanding of tumor biology suggests that breast cancer is a group of diseases with different intrinsic molecular subtypes. Anatomic staging system alone is insufficient to provide future outcome information. The American Joint Committee on Cancer （AJCC） expert panel updated the 8th edition of the staging manual with prognostic stage groups by incorporating biomarkers into the anatomic stage groups. In this study, we retrospectively analyzed the data from our center in China using the anatomic and prognostic staging system based on the AJCC 8th edition staging manual. Methods： We reviewed the data from January 2008 to December 2014 for cases with Luminal B Human Epidermal Growth Factor Receptor 2 （HER2）-negative breast cancer in our center. All cases were restaged using the AJCC 8th edition anatomic and prognostic staging system. The Kaplan-Meier method and log-rank test were used to compare the survival differences between different subgroups. SPSS software version 19.0 （IBM Corp., Armonk, NY, USA） was used for the statistical analyses. Results： This study consisted of 796 patients with Luminal B HER-negative breast cancer. The 5-year disease-free survival （DFS） of 769 Stage I-III patients was 89.7%, and the 5-year overall survival （OS） of all 796 patients was 91.7%. Both 5-year DFS and 5-year OS were significantly different in the different anatomic and prognostic stage groups, There were 372 cases （46.7%） assigned to a different group. The prognostic Stage II and III patients restaged from anatomic Stage III had significant differences in 5-year DFS （v2 = 11.319; P = 0.001） and 5-year OS （χ2 = 5.225, P = 0.022）. In addition, cases restaged as prognostic Stage I, II, or III from the anatomic Stage II group had statistically significant differences in 5-year DFS （χ2 = 6.510, P = 0.039） but no significant differences in 5-year OS （χ2 = 5.087, P = 0.079）. However, the restaged prognostic Stage I and II cases from anatomic Stage I had no statistically significant differences in either 5-year DFS （χ2 = 0.440, P = 0.507） or 5-year OS （χ2= 1.530, P = 0.216）. Conclusions： The prognostic staging system proposed in the AJCC 8th edition refines the anatomic stage group in Luminal B HER2-negative breast cancer and will lead to a more personalized approach to breast cancer treatment.
文摘1文献来源 Becker A, Crombag L, Heideman DA, et al. Retreatment with Erlotinib： Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment [J]. Eur J Cancer, 2011,47（17） ：2603-2606.2
